{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:05:22Z","timestamp":1761512722598},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:p>In this study we evaluated the diagnostic accuracy for antiphospholipid syndrome (APS) of new fully automated immunoassays for anticardiolipin (aCL) and anti\u2010\u03b22 glycoprotein I (anti\u2010\u03b22\u2010GPI) auto\u2010antibody detection (EliA\u2010Phadia), and compared the results with those obtained with Orgentec and Inova ELISA methods. Sixty\u2010two APS patients and 123 controls (20 syphilis, 33 Lyme disease, 30 HCV infection and cryoglobulinemia, 40 healthy subjects) were studied. Using the 99<jats:sup>th<\/jats:sup> percentile cutoff, the sensitivity and specificity of EliA aCL IgG, aCL IgM, anti\u2010\u03b22\u2010GPI IgG, and anti\u2010\u03b22\u2010GPI IgM were 69.4% and 81.9%, 64.5% and 86.7%, 64.5% and 98.8%, and 53.2% and 92.8%, respectively. Using the Sydney criteria cutoff (&gt;40 GPL\/MPL units), sensitivity and specificity of EliA aCL IgG and aCL IgM were 45.2% and 98.8%, and 35.5% and 97.5%, respectively. The best diagnostic efficiency was obtained combining the aCL tests (&gt;40 GPL\/MPL units) with the anti\u2010\u03b22\u2010GPI tests (sensitivity 85.7%, specificity 90.4%). The area under the ROC curves for EliA, Orgentec, and Inova methods were 0.870, 0.940, and 0.850 for aCL IgG; 0.820, 0.820, and 0.820 for aCL IgM; 0.910, 0.960, and 0.920 for anti\u2010\u03b22\u2010GPI IgG; 0.840, 0.840, and 0.820 for anti\u2010\u03b22\u2010GPI IgM, respectively. Finally, the overall agreement between EliA assays and the other two ELISA methods ranged from moderate (anti\u2010\u03b22\u2010GPI IgG EliA versus Orgentec: Cohen's <jats:italic>k<\/jats:italic>= 0.426) to good (anti\u2010\u03b22\u2010GPI IgM EliA vs. Inova: <jats:italic>k<\/jats:italic>= 0.841). In conclusion, newly developed EliA methods for antiphospholipid antibody detection perform similarly to other ELISA assays and represent a useful tool for APS laboratory diagnosis in daily practice.<\/jats:p>","DOI":"10.1111\/j.1749-6632.2009.04659.x","type":"journal-article","created":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T22:02:36Z","timestamp":1251842556000},"page":"21-27","source":"Crossref","is-referenced-by-count":20,"title":["Accuracy of the First Fully Automated Method for Anti\u2010cardiolipin and Anti\u2010\u03b22 Glycoprotein I Antibody Detection for the Diagnosis of Antiphospholipid Syndrome"],"prefix":"10.1111","volume":"1173","author":[{"given":"D.","family":"Villalta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Alessio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tampoia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Da Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Da Re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Tozzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Bizzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,9]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6399.1088"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(05)80194-5"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.11.4120"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91374-J"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91697-9"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02772250"},{"key":"e_1_2_7_8_2","first-page":"1899","article-title":"Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti\u2010\u03b22\u2010glycoprotein I than with antiphospholipid antibodies","volume":"22","author":"Cabiedes J.","year":"1995","journal-title":"J. Rheumatol."},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.01753.x"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613606"},{"key":"e_1_2_7_12_2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2003.08.023","article-title":"Does the anti\u2010\u03b22\u2010glycoprotein I antibody provide additional information in patients with thrombosis?","volume":"111","author":"Lee E.Y.","journal-title":"Thromb. Res."},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3334"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-863808"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.07.014"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1085477"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1085478"},{"key":"e_1_2_7_18_2","first-page":"215","article-title":"Evaluation of anti\u2010cardiolipin antibody test: report of an international workshop held April 4 1986","volume":"68","author":"Harris E.N.","year":"1986","journal-title":"Clin. Exp. Immunol."},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1159\/000093564"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1616089"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00910.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03121.x"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.06.002"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2007.11.014"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1085476"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1749-6632.2009.04659.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1749-6632.2009.04659.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T07:35:57Z","timestamp":1695627357000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1749-6632.2009.04659.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1111\/j.1749-6632.2009.04659.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1749-6632.2009.04659.x","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}